MediciNova Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
6,700.50
11,669.40
22,076.70
24,118.00
27,991.70
62,313.40
Total Accounts Receivable
6,008.60
-
-
-
-
-
Other Current Assets
1,673.60
463.50
649.50
585.80
336.60
444.90
Total Current Assets
14,382.60
12,132.90
22,726.20
24,703.80
28,328.30
62,758.40
Net Property, Plant & Equipment
82.40
44.80
20.40
90.70
62.90
53.10
Total Investments and Advances
681.00
684.80
650.50
618.30
616.70
-
Intangible Assets
14,400.20
14,400.20
14,400.20
14,400.20
14,400.20
14,400.20
Other Assets
-
10.70
109.00
-
11.00
11
Total Assets
29,546.20
27,273.50
37,906.30
39,813.10
43,419.10
77,222.70
Accounts Payable
33.90
-
-
-
-
Other Current Liabilities
426.50
1,594.00
1,490.50
1,630.10
2,881.00
Total Current Liabilities
460.40
1,594.00
1,490.50
1,630.10
2,881.00
Deferred Taxes
1,956.00
1,956.00
1,956.00
1,956.00
201.80
Other Liabilities
1,704.10
1,712.90
1,706.80
1,695.10
1,694.20
Total Liabilities
4,120.50
5,262.90
5,153.30
5,281.20
4,776.90
Common Equity (Total)
25,423.60
22,008.40
32,750.80
34,531.90
38,642.10
Total Shareholders' Equity
25,425.80
22,010.60
32,753.00
34,531.90
38,642.10
Total Equity
25,425.80
22,010.60
32,753.00
34,531.90
38,642.10
Liabilities & Shareholders' Equity
29,546.20
27,273.50
37,906.30
39,813.10
43,419.10
Preferred Stock (Carrying Value)
2.20
2.20
2.20
-
-

About MediciNova

View Profile
Address
4275 Executive Square
La Jolla California 92037
United States
Employees -
Website http://www.medicinova.com
Updated 07/08/2019
MediciNova, Inc. is a biopharmaceutical company, which engages in acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. The firm's development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.